CoChat
Sign Up
Cited by 30

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction

Li, Chao, Ding, Lei, Sun, Chiao-Wang, Wu, Li-Chen, Zhou, Dewang, Pawlik, Kevin M., Khodadadi-Jamayran, Alireza, Westin, Erik, Goldman, Frederick D., Townes, Tim M.·2016·Scientific Reports
DOI 10.1038/srep30422PMC PMC4961958
Open this paper in CoChat — free account

Abstract

CRISPR/Cas enhanced correction of the sickle cell disease (SCD) genetic defect in patient-specific induced Pluripotent Stem Cells (iPSCs) provides a potential gene therapy for this debilitating disease. An advantage of this approach is that corrected iPSCs that are free of off-target modifications can be identified before differentiating the cells into hematopoietic progenitors for transplantation. In order for this approach to be practical, iPSC generation must be rapid and efficient. Therefore, we developed a novel helper-dependent adenovirus/Epstein-Barr virus (HDAd/EBV) hybrid reprogramming vector, rCLAE-R6, that delivers six reprogramming factors episomally. HDAd/EBV transduction of keratinocytes from SCD patients resulted in footprint-free iPSCs with high efficiency. Subsequently, the sickle mutation was corrected by delivering CRISPR/Cas9 with adenovirus followed by nucleoporation with a 70 nt single-stranded oligodeoxynucleotide (ssODN) correction template. Correction efficiencies of up to 67.9% (β A /[β S +β A ]) were obtained. Whole-genome sequencing (WGS) of corrected iPSC lines demonstrated no CRISPR/Cas modifications in 1467 potential off-target sites and no modifications in tumor suppressor genes or other genes associated with pathologies. These results demonstrate that adenoviral delivery of reprogramming factors and CRISPR/Cas provides a rapid and efficient method of deriving gene-corrected, patient-specific iPSCs for therapeutic applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep30422

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 44

  1. Thomas, E. D. & Blume, K. G. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 5, 341–6 (1999). · DOI
  2. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–76 (2006). · DOI · Paper page
  3. Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797–801 (2009). · DOI · Paper page
  4. Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 8, 409–12 (2011). · DOI · Paper page
  5. Okita, K. et al. An Efficient Non-viral Method to Generate Integration-Free Human iPS Cells from Cord Blood and Peripheral Blood Cells. Stem Cells (2012). · DOI
  6. Schlaeger, T. M. et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol 33, 58–63 (2015). · DOI
  7. Tachibana, M. et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 153, 1228–38 (2013). · DOI
  8. Trounson, A. & DeWitt, N. D. Pluripotent stem cells from cloned human embryos: success at long last. Cell Stem Cell 12, 636–8 (2013). · DOI
  9. Chung, Y. G. et al. Human somatic cell nuclear transfer using adult cells. Cell Stem Cell 14, 777–80 (2014). · DOI
  10. Yamada, M. et al. Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells. Nature 510, 533–6 (2014). · DOI
  11. Feng, B. et al. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol 11, 197–203 (2009). · DOI
  12. Han, J. et al. Tbx3 improves the germ-line competency of induced pluripotent stem cells. Nature 463, 1096–100 (2010). · DOI · Paper page
  13. Zhao, Y. et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 3, 475–9 (2008). · DOI · Paper page
  14. Maekawa, M. et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature 474, 225–9 (2011). · DOI
  15. Edel, M. J. et al. Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1. Genes Dev 24, 561–73 (2010). · DOI
  16. Subramanyam, D. et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 29, 443–8 (2011). · DOI
  17. Onder, T. T. et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598–602 (2012). · DOI
  18. Li, M. et al. Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res 21, 1740–4 (2011). · DOI
  19. Zou, J., Mali, P., Huang, X., Dowey, S. N. & Cheng, L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118, 4599–608 (2011). · DOI
  20. Sebastiano, V. et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29, 1717–26 (2011). · DOI
  21. Yan, W., Smith, C. & Cheng, L. Expanded activity of dimer nucleases by combining ZFN and TALEN for genome editing. Sci Rep 3, 2376 (2013). · DOI
  22. Huang, X. et al. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation. Stem Cells 33, 1470–9 (2015). · DOI
  23. Miyaoka, Y. et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat Methods 11, 291–3 (2014). · DOI
  24. Kochanek, S. et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 93, 5731–6 (1996). · DOI
  25. Parks, R. J. et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93, 13565–70 (1996). · DOI · Paper page
  26. Morsy, M. A. et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95, 7866–71 (1998). · DOI
  27. Morral, N. et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 96, 12816–21 (1999). · DOI
  28. Ehrhardt, A. & Kay, M. A. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo . Blood 99, 3923–30 (2002). · DOI
  29. Kreppel, F. & Kochanek, S. Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol 78, 9–22 (2004). · DOI
  30. Dorigo, O. et al. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol 78, 6556–66 (2004). · DOI
  31. Gallaher, S. D., Gil, J. S., Dorigo, O. & Berk, A. J. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector. J Virol 83, 3249–57 (2009). · DOI
  32. Gil, J. S., Gallaher, S. D. & Berk, A. J. Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: long-term transgene expression in immunocompetent mice. Gene Ther 17, 1288–93 (2010). · DOI
  33. Chang, C. W. et al. Polycistronic lentiviral vector for “hit and run” reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27, 1042–9 (2009). · DOI
  34. Mali, P. et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 28, 713–20 (2010). · DOI · Paper page
  35. Aasen, T. et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26, 1276–84 (2008). · DOI · Paper page
  36. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–9 (2013). · DOI · Paper page
  37. Hoban, M. D. et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 125, 2597–604 (2015). · DOI · Paper page
  38. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31, 822–6 (2013). · DOI · Paper page
  39. Rice, P., Longden, I. & Bleasby, A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16, 276–7 (2000). · DOI · Paper page
  40. Holkers, M. et al. Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat Methods 11, 1051–7 (2014). · DOI · Paper page
  41. Suzuki, K. et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 15, 31–6 (2014). · DOI · Paper page
  42. Palmer, D. & Ng, P. Improved system for helper-dependent adenoviral vector production. Mol Ther 8, 846–52 (2003). · DOI · Paper page
  43. Wu, L. C. et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108, 1183–8 (2006). · DOI
  44. Chang, C. W. et al. Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. Cell Rep 12, 1668–77 (2015). · DOI

Cited by

Sorted by citations

Metadata

Authors
Li, C., Ding, L., Sun, C.-W., Wu, L.-C., Zhou, D., Pawlik, K. M., Khodadadi-Jamayran, A., Westin, E., Goldman, F. D., & Townes, T. M.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2016-07-27
Volume
6
Issue
1
ISSN
2045-2322
DOI
10.1038/srep30422
PMC
PMC4961958
Cited by
30
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review